Loading...
XFRA
VSC
Market cap1mUSD
Dec 16, Last price  
0.10EUR
Name

4Sc AG

Chart & performance

D1W1MN
XFRA:VSC chart
P/E
—
P/S
3.33
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.53%
Rev. gr., 5y
-40.78%
Revenues
304k
-30.28%
4,353,0004,904,0007,055,0002,296,0002,060,0004,197,0004,173,0002,196,0002,252,00014,109,000436,000304,000
Net income
-8m
L-42.64%
-13,217,000-10,525,000-9,696,000-8,228,000-11,355,000-10,960,000-17,659,000-13,962,000-18,988,000-9,628,000-14,361,000-8,237,000
CFO
-10m
L+1.76%
-15,174,000-6,986,000-8,372,000-8,958,000-12,922,000-8,541,000-16,162,000-12,698,000-15,688,000-12,069,000-9,383,000-9,548,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

4SC AG is a clinical-stage biopharmaceutical company dedicated to advancing novel small-molecule therapeutics for oncology indications characterized by significant unmet patient needs. Among its lead candidates is Resminostat, an orally administered histone deacetylase inhibitor, currently undergoing Phase II clinical assessment for cutaneous T-cell lymphoma. Additionally, Domatinostat, an oral small molecule, is being evaluated in a Phase Ib/II trial for melanoma and a separate Phase II clinical trial for gastrointestinal tumors. Furthermore, 4SC AG strategically out-licenses its cancer-focused compounds to other pharmaceutical and biotechnology partners. The company also collaborates with the Netherlands Cancer Institute to investigate Domatinostat's efficacy in a neoadjuvant setting for melanoma patients. Founded in 1997, 4SC AG maintains its corporate headquarters in Planegg, Germany.
URL
https://www.4sc.de
IPO date
Feb 25, 2008
Employees
33
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT